Description: Altamira Therapeutics is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne pathogens and allergens (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol 'EARS.'
Home Page: altamiratherapeutics.com
CYTO Technical Analysis
Clarendon House
Hamilton,
HM 11
Bermuda
Phone:
441 295 5950
Officers
| Name | Title |
|---|---|
| Dr. Thomas Meyer Ph.D. | Founder, Chairman, CEO & MD |
| Mr. Marcel Gremaud CPA | Chief Financial Officer |
| Dr. Samuel A. Wickline M.D. | Chief Scientific Officer |
| Dr. Covadonga Pañeda | Chief Devel. Officer |
| Mr. Jean Lechance | Unit Head of OTC Consumer Health Bus. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7283 |
| Price-to-Sales TTM: | 4.2592 |
| IPO Date: | 2014-08-06 |
| Fiscal Year End: | December |
| Full Time Employees: | 14 |